Using pharmacogenetics to personalize treatment outcome to ranibizumab (Lucentis) for the eye disease age-related macular degeneration (AMD)

Funding Activity

Website
http://purl.org/au-research/grants/nhmrc/1008979

Funding Status
Closed

Does something not look right? The information on this page has been harvested from data sources that may not be up to date. We continue to work with information providers to improve coverage and quality. To report an issue, use the .

Funded Activity Summary

The drug Lucentis has revolutionized the treatment of age-related macular degeneration, one of the commonest causes of severe vision loss in Australia. Unfortunately, up to 25% of patients continue to lose vision despite this treatment. We will use the latest gene chip technology to identify the genetic variant responsible for this poor response. Having this information will allow us to personalise treatment for the patient leading to improvement in their vision.

Funded Activity Details

Start Date: 01-01-2011

End Date: 01-01-2014

Funding Scheme: Project Grants

Funding Amount: $623,891.00

Funder: National Health and Medical Research Council

Research Topics

ANZSRC Field of Research (FoR)

Ophthalmology

ANZSRC Socio-Economic Objective (SEO)

There are no SEO codes available for this funding activity

Other Keywords

ageing | disease aetiology | eye disease | genetic analysis | macular degeneration | pharmacogenetics | prediction | treatment outcomes

Related Links